Phase 2 ALL Clinical Trials
1,169 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 1,169 trials
Recruiting
Phase 2
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Lung Neuroendocrine NeoplasmAdvanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine Tumor+9 more
National Cancer Institute (NCI)70 enrolled29 locationsNCT04665739
Recruiting
Phase 2
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+1 more
National Cancer Institute (NCI)20 enrolled8 locationsNCT07061951
Recruiting
Phase 2
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaB-ALL
National Cancer Institute (NCI)20 enrolled1 locationNCT07328503
Recruiting
Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled580 locationsNCT03866382
Recruiting
Phase 1Phase 2
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Non-small Cell Lung CancerAdvanced Solid TumorsSmall Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.260 enrolled1 locationNCT07208773
Recruiting
Phase 1Phase 2
Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
Non-small Cell Lung Cancer
Second Affiliated Hospital of Nanchang University45 enrolled1 locationNCT07655622
Recruiting
Phase 2
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled127 locationsNCT05006716
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Neuroendocrine CarcinomaCarcinoma, NeuroendocrineTumor, Neuroendocrine+2 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06406465
Recruiting
Phase 2
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell Carcinoma+15 more
National Cancer Institute (NCI)180 enrolled77 locationsNCT07195734
Recruiting
Phase 1Phase 2
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 1Phase 2
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
SCLCSmall Cell Lung CancerSCLC,Extensive Stage+2 more
Peking University First Hospital30 enrolled1 locationNCT07508852
Recruiting
Phase 1Phase 2
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Breast CancerOvarian CancerEndometrial Cancer+2 more
AstraZeneca460 enrolled67 locationsNCT05123482
Recruiting
Phase 1Phase 2
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
Locally Advanced/Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited114 enrolled10 locationsNCT06414460
Recruiting
Phase 2
Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
PARP InhibitorPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+1 more
Ronald Buckanovich48 enrolled1 locationNCT05538091
Recruiting
Phase 2
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AbbVie150 enrolled75 locationsNCT06568939
Recruiting
Phase 2
Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation
Non-small Cell Lung CancerRadiation Induced Lung Injury (RILI)
University Health Network, Toronto150 enrolled1 locationNCT06634056
Recruiting
Phase 2
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
Non-small Cell Lung Cancer Metastatic
Memorial Sloan Kettering Cancer Center56 enrolled8 locationsNCT06741085
Recruiting
Phase 1Phase 2
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Small Cell Lung Cancer ( SCLC )Transformed Small Cell Lung Cancer
Misty Shields16 enrolled1 locationNCT07153055